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Alopecia areata is a common form of hair loss in which autoimmune-mediated destruction of hair follicles causes
patchy hair loss, for which there is no adequate therapy. Parathyroid hormone (PTH) induces the hair cycle and
promotes hair growth. PTH-CBD is a fusion protein of PTH and a bacterial collagen-binding domain (CBD),
leading to targeted delivery to and retention in the skin collagen. We tested the effects of a single dose of PTH-
CBD (low or high dose) on an animal model for alopecia areata, the C3H/HeJ engrafted mouse. In all the treated
animals, there was a rapid (1–4 days) increase in hair growth, with sustained effects observed over a 2-month
period (7/10 total treated miceo40% hair loss based on gray scale analysis, vs. 2/5 in vehicle control animals).
Histological examination revealed massive stimulation of anagen VI hair follicles in treated animals despite an
ongoing immune response. PTH-CBD thus shows promise as a therapy for alopecia areata, likely in conjunction
with a mild immune suppressant, such as hydrocortisone cream.
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INTRODUCTION
Alopecia areata is a common form of hair loss and affects
1.7% of population. It is an autoimmune-mediated destruction
of anagen phase hair follicles, which leads to patchy hair loss.
It can progress to alopecia totalis (loss of all hair on the head)
or alopecia universalis (loss of all hair on body). Currently,
there is no adequate therapy. Parathyroid hormone (PTH)
activates receptors in keratinocytes, activating Wnt signaling
and increasing production of beta-catenin and LEF-1 (lym-
phoid enhancer-binding factor-1; Foley et al., 2001). Beta-
catenin activates the hair cycle by promoting transition of hair
follicles to the anagen phase (Huelsken et al., 2001). PTH
agonists and antagonists have been shown to modulate the
hair cycle (Schilli et al., 1997). PTH-CBD is a fusion protein of
the active portion of PTH(1–33), linked to a bacterial collagen-
binding domain (CBD) derived from ColH collagenase
(Clostridium histolyticum). We hypothesized that PTH-CBD
would activate hair follicles and promote hair growth in
alopecia areata.
RESULTS
Mice were monitored for 2 months. There were apparent early
effects of treatment, with increased hair growth 1 and 4 days
after administration of PTH-CBD, most evident in animals
receiving the highest dose. These results are confirmed with
gray scale analysis, which showed both a rapid increase in
hair growth and sustained effects observed over a 2-month
period (7/10 total treated miceo40% hair loss based on gray




Figure 1. PTH-CBD (a fusion protein of parathyroid hormone and a bacterial
collagen-binding domain) treatment in C3H/HeJ engrafted mice. Shown are
representative vehicle and PTH-CBD-treated mice, with photographs of
(a, b) dorsal view and (c, d) skin histology ( 10), 60 days after treatment.
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examination revealed marked increase in the number of
anagen VI follicles in PTH-CBD-treated animals relative to
vehicle controls (Figure 1). There was evidence of ongoing
immune response in most treated animals, as expected.
Interestingly, these histological features were present in all
treated animals, with and without grossly apparent hair
loss, and suggests that combined treatment with mild
immunosuppressant may result in more consistent responses.
The antagonist compound appeared to have little effect on
hair growth, follicle number, or immune response.
DISCUSSION
C3H/HeJ engrafted animals treated with PTH-CBD showed
rapid improvements in hair growth, evident after 1 day of
treatment, and persist for 1–2 weeks. There was a marked
increase in the number of growing hair follicles despite an
ongoing immune reaction. PTH-CBD shows promise as a
therapy for alopecia areata, particularly in conjunction with a
mild immune suppressant, such as hydrocortisone cream.
METHODS
20 Female C3H/HeJ engrafted mice were obtained from Jackson
Laboratories (Bar Harbor, ME). Mice were divided into tiers based on
degree of hair loss; each tier was individually randomized into four
groups: vehicle, low-dose PTH-CBD (320 mcg/kg), high-dose PTH-
CBD (1,000 mcg/kg), and PTH(7–33)-CBD (antagonist  320 mcg/kg).
This protocol was approved by Montefiore Medical Center IACUC,
protocol #11-06-240.
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